Oxygenta Pharmaceutical Ltd (OXYGENTAPH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Oxygenta Pharmaceutical Ltd on NSE and BSE, with an AI summary of each filing.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
Others (Uncategorized) · 01 Oct 2026, 11:28 pm
Oxygenta Pharmaceutical Secures Land Allotment for Rs 6.75 Crore in Telangana Telangana Industrial Infrastructure Corporation Limited issued a final allotment letter on 1st Oct'26 to Oxygenta Pharmaceutical Limited for 36,421 sq. meters of land (Plot No. UDL-1) at UDL-Aroor, Sangareddy District, Telangana. The transaction entails a total consideration of Rs 6.75 crore (Rs 6,75,24,534). The acquisition aims to support ongoing business operations, facilitate future capacity expansion, and build infrastructure to meet long-term strategic growth requirements.
Disclosure under Regulation 44(3) of SEBI (LODR), Regulations, 2015.
Annual General Meeting · 21 Aug 2026, 10:21 pm
Oxygenta Pharma AGM: All Resolutions Passed With Overwhelming Majority Oxygenta Pharmaceutical announced that all resolutions proposed at its 33rd Annual General Meeting on 21st Aug'26 were passed with the requisite majority. Key approvals include the adoption of FY26 financial statements, director appointments, and material related party transactions (RPTs) with holding company Virupaksha Organics. Public non-institutional shareholders voted overwhelmingly in favor of all proposals, with approval rates exceeding 99.99% on most resolutions. Total voter turnout represented 12.09% of the company's total share capital. The promoter group did not participate in the voting process.
Outcome of 33rd Annual General Meeting held on 21.08.2026.
Annual General Meeting · 21 Aug 2026, 10:17 pm
Newspaper Advertisement for Notice of AGM scheduled to be held on 21st August, 2026.
Annual General Meeting · 31 Jul 2026, 5:39 pm
Intimation of Book Closure and Cut-off Date for the AGM
Annual General Meeting · 30 Jul 2026, 10:42 pm
Submission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR), Regulations, 2015
Others (Uncategorized) · 30 Jul 2026, 10:36 pm
Notice of 33rd Annual General Meeting for the Financial Year 2025-26.
Annual General Meeting · 30 Jul 2026, 10:30 pm
Appointment of Cost Auditor for the Financial Year 2026-27.
Change in Management · 27 Jul 2026, 11:44 pm
Oxygenta Q1FY27: Revenue Jumps YoY While Losses Narrow Oxygenta Pharmaceutical reported Q1FY27 revenue from operations of ₹3,699.69 lakhs, a 144.4% YoY increase. Net loss for the quarter narrowed to ₹210.37 lakhs from ₹610.61 lakhs in Q1FY26, while loss before tax improved to ₹250.73 lakhs from ₹814.80 lakhs YoY. Sequentially, revenue declined 25.4% QoQ from ₹4,961.40 lakhs. The company also announced its FY26 AGM will be held on 21st Aug'26 and appointed M/s. PCR & Associates as Cost Auditors for FY27.
Un-audited Financial Results for the Quarter ended 30.06.2026.
Financial Result · 27 Jul 2026, 11:42 pm
Oxygenta Pharma Q1FY27: Revenue Jumps YoY, Losses Narrow Oxygenta Pharmaceutical reported Q1FY27 revenue from operations at ₹3,699.69 lakhs, a 144.4% YoY increase from ₹1,513.47 lakhs but a 25.4% QoQ decline. The net loss for the quarter narrowed significantly to ₹210.37 lakhs from a loss of ₹610.61 lakhs in Q1FY26. QoQ, the net loss widened from ₹170.39 lakhs. Basic EPS for the quarter was (₹0.57) compared to (₹1.65) YoY. The Board approved the results on 27th Jul'26 and appointed M/s. PCR & Associates as Cost Auditors for FY27.
Un-audited Financial results for the Quarter ended 30.06.2026.
Outcome · 27 Jul 2026, 11:35 pm
Oxygenta Pharma: Revenue Jumps 144% YoY, Loss Before Tax Narrows in Q1FY27 Oxygenta Pharmaceutical reported strong top-line growth for Q1 ended 30th Jun'26, with revenue from operations surging 144% YoY to ₹3,699.69 lakhs. Sequentially, revenue declined 25% QoQ. The company's loss before tax significantly narrowed to ₹250.73 lakhs from a loss of ₹814.80 lakhs in the prior year's quarter. Total expenses increased 69% YoY to ₹3,952.75 lakhs. Net loss for the quarter stood at ₹210.37 lakhs, an improvement from ₹610.61 lakhs YoY. The board also scheduled the AGM for 21st Aug'26.
Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2026 ,inter alia, to consider and approve 1. Unaudited Financial ....
Intimation · 25 Jul 2026, 5:30 am
Oxygenta Pharmaceutical Board Meeting Set for Jul 25, '26 to Approve Q1 Results Oxygenta Pharmaceutical Ltd (BSE: 524636) announced its Board of Directors will meet on Sat, 25th Jul'26. The primary agenda is to consider and approve the un-audited financial results for the first quarter ending 30th Jun'26. The board will also review the limited review report for the same period. Any other business may be discussed with the permission of the Chair.
Change in Management by way of appointment of Additional Directors and Internal Auditor.
Change in Management · 23 May 2026, 11:17 pm
Oxygenta Q4FY26 Loss Narrows, Revenue Flat; Announces Key Board Appointments Oxygenta Pharmaceutical reported a Q4FY26 net loss of ₹170.39 lakhs, narrowing from a ₹215.12 lakh loss YoY, on revenue of ₹4,961.40 lakhs, flat YoY. For the full year FY26, the net loss widened to ₹1,757.17 lakhs from ₹1,029.83 lakhs in FY25, while revenue grew 3.4% YoY to ₹11,298.19 lakhs. The board approved results and appointed Amireddy Venkatesu Reddy as Additional Executive Director and Janardhana Reddy Yeddula as an Additional Independent Director, effective 23 May'26, subject to shareholder approval.
Audited Financial Results for the Quarter and Year ended 31.03.2026.
Financial Result · 23 May 2026, 11:13 pm
Oxygenta Reports Wider Losses for Q4 & FY26; Appoints New Directors Oxygenta Pharmaceutical's Q4 FY26 net loss narrowed to ₹170.39 Lakhs from a loss of ₹215.12 Lakhs YoY, while revenue was flat at ₹4,961.40 Lakhs. For the full year FY26, the company reported a net loss of ₹1,757.17 Lakhs, widening from ₹1,029.83 Lakhs in FY25. Revenue for FY26 increased 3.4% YoY to ₹11,298.19 Lakhs. The Board appointed Amireddy Venkatesu Reddy as Additional Executive Director and Janardhana Reddy Yeddula as Additional Independent Director, both effective from 23rd May'26, subject to shareholder approval.
Outcome of the Board meeting held on 23rd May, 2026.
Outcome · 23 May 2026, 11:05 pm
Oxygenta Pharmaceutical Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 4,961 (+0.3% YoY | +46.2% QoQ) ■ EBITDA: 11.4 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 0.2 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: -170 (+20.8% YoY | +64.8% QoQ) ■ EPS (INR): -0.45 (+25.0% YoY | +65.9% QoQ)
Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve 1. Audited Financial ....
Intimation · 23 May 2026, 5:30 am
Oxygenta Pharma Board to Approve Q4 & FY26 Results on 23-May-26 Oxygenta Pharmaceutical Ltd (BSE: 524636) announced its Board of Directors will meet on 23-May-26 to consider and approve key agenda items. The board will review the audited financial results for the quarter and fiscal year ended 31-Mar-26. Additionally, the corresponding audit report for the year will be considered for approval. Any other business may also be discussed with the permission of the Chair. This meeting is a critical event for the company's full-year financial disclosures and performance assessment.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 27 Apr 2026, 9:10 pm
Oxygenta Pharmaceutical Confirms It Does Not Qualify as a Large Corporate Oxygenta Pharmaceutical Limited has formally notified the BSE on 27 Apr'26 that it does not fall under the SEBI framework for a "Large Corporate" (LC) for FY 2025-26. This classification exempts the company from the mandatory requirement to raise a portion of its funding through the issuance of debt securities. The filing confirmed that there were no mandatory borrowing requirements, actual debt borrowings, or associated shortfalls for the period. Oxygenta is a subsidiary of Virupaksha Organics Limited.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 27 Apr 2026, 9:03 pm
Oxygenta Pharma Confirms It Does Not Qualify as a Large Corporate On 27-Apr'26, Oxygenta Pharmaceutical confirmed it does not qualify as a "Large Corporate" under SEBI's framework for FY26-27. While its shares are listed, it fails to meet the other criteria: outstanding long-term borrowings of ₹1,000 crore or more and a credit rating of "AA" or above. The company reported outstanding borrowing of ₹107.31 crore as of 31-Mar'26. Consequently, the initial disclosure requirement under the SEBI circular is not applicable.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Discloure Requirements) Regulations, 2015.
Others (Uncategorized) · 20 Feb 2026, 10:06 pm
Oxygenta Pharma Gets Favorable Tax Order, Disputed Demand Annulled Oxygenta Pharmaceutical received an order on 19 Feb'26 from the State Tax authority setting aside a disputed demand of Rs. 41.31 lakh. The demand, originally raised for the tax period 01 Apr'17 to 31 Mar'18, related to Input Tax Credit on non-business transactions. The company's appeal was successful, and the order has been annulled based on its representations. The company states there will be no financial impact from this settlement, as the disputed demand is now voided.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd
Acquisition/ Disposal of Shares · 14 Feb 2026, 4:31 pm
Virupaksha Organics Boosts Stake in Oxygenta Pharmaceutical via Open Market Purchase Virupaksha Organics Limited, a promoter of Oxygenta Pharmaceutical Ltd (BSE: 524636), acquired 2,23,632 equity shares through an open market purchase on 13 Feb'26. This transaction represents 0.60% of Oxygenta's total voting capital. Following the acquisition, Virupaksha Organics' total shareholding in the company increased from 2,06,73,343 shares (55.90%) to 2,08,96,975 shares (56.50%). The purchase was disclosed under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reflecting a consolidation of promoter holding.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd
Acquisition/ Disposal of Shares · 13 Feb 2026, 11:23 pm
Promoter Virupaksha Organics Acquires Additional Stake in Oxygenta Pharmaceutical Virupaksha Organics Ltd, a promoter of Oxygenta Pharmaceutical Ltd (BSE: 524636), acquired 2,23,632 equity shares via an open market purchase on 13-Feb-'26. This transaction represents 0.60% of the total share capital. Following the acquisition, the promoter's holding in Oxygenta Pharmaceutical increased from 55.90% (2,06,73,343 shares) to 56.50% (2,08,96,975 shares). This move consolidates the promoter group's stake in the company. The total paid-up equity capital of Oxygenta remains at Rs. 36.98 crore.
Un-audited Results for the Quarter and nine months ended 31.12.2025.
Financial Result · 04 Feb 2026, 11:39 pm
Oxygenta Pharma Reports Widening Net Loss for Q3FY26 Amid Flat Revenue Oxygenta Pharmaceutical Limited reported unaudited results for the quarter ending 31 Dec'25, posting a net loss of Rs. 484.30 Lakhs, an increase from a loss of Rs. 392.82 Lakhs YoY. Total income from operations remained flat at Rs. 3,393.09 Lakhs compared to Rs. 3,369.43 Lakhs in Q3FY25. The loss before tax widened to Rs. 632.65 Lakhs from Rs. 496.18 Lakhs YoY, driven by higher material and finance costs. The Board also approved the reconstitution of the Internal Complaints Committee, effective 04 Feb'26.
With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04th February, 2026, ....
Outcome · 04 Feb 2026, 11:32 pm
Oxygenta Pharmaceutical Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakh) ■ Revenue: 3393 (+0.7% YoY | +138.2% QoQ) ■ EBITDA: -408 (-5.4% YoY | +12.0% QoQ) ■ EBITDA Margin (%): -12.0 (-54 bps YoY | +2049 bps QoQ) ■ PAT: -484 (-23.3% YoY | +1.8% QoQ) ■ EPS (INR): -1.32 (-17.9% YoY | +0.8% QoQ)
Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 ,inter alia, to consider and approve 1. Un-audited Financial ....
Intimation · 04 Feb 2026, 5:30 am
Oxygenta Pharma Board Meeting Scheduled for 04th Feb'26 to Approve Q3 Results Oxygenta Pharmaceutical Ltd (BSE: 524636) will hold a Board Meeting on 04th Feb'26 to consider and approve its un-audited financial results for the quarter ended 31st Dec'25. The agenda also includes the consideration of the Limited Review Report for the same period. This meeting will determine the company's financial performance for the third quarter of the fiscal year.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd
Acquisition/ Disposal of Shares · 17 Dec 2025, 10:20 pm
Promoter Virupaksha Organics Increases Stake in Oxygenta Pharmaceutical Virupaksha Organics Ltd, a promoter entity, acquired 1,95,885 equity shares of Oxygenta Pharmaceutical Ltd (BSE: 524636) via an open market purchase on 15-Dec-25. This transaction represents 0.53% of the company's total voting capital. Following the acquisition, Virupaksha Organics' total holding in Oxygenta increased from 55.37% (2,04,77,458 shares) to 55.90% (2,06,73,343 shares), further consolidating its promoter stake. The total paid-up capital of Oxygenta remains at Rs. 36,98,35,000.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd
Acquisition/ Disposal of Shares · 17 Dec 2025, 9:55 pm
Promoter Virupaksha Organics Acquires Additional Stake in Oxygenta Pharmaceutical Promoter Virupaksha Organics Ltd acquired 1,95,885 equity shares (0.53% stake) of Oxygenta Pharmaceutical Ltd via an open market purchase on 15-Dec'25. This transaction increases the promoter's total holding in Oxygenta from 2,04,77,458 shares (55.37%) to 2,06,73,343 shares (55.90%). The acquisition signals strengthening promoter conviction in the company. Oxygenta's total paid-up equity capital remains at Rs. 36.98 crore, comprising 3,69,83,500 shares of Rs. 10 each.